Skip to main content

Institutional intelligence for Sudeep Pharma Ltd

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Tracked super investors holding ≥1%

Ownership breakdown

Category totals from the official quarterly Shareholding Pattern filing (Jun 2026). Sums to 100.00%.

  • Promoters76.15%
  • FII1.81%
  • Mutual Funds5.47%
  • DII (ex-MF)10.18%
  • Retail & others6.39%
  • Super Investors 1.33%(subset)
  • 1% Club 8.86%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive. View filing

Holder details (≥1% disclosed names)

Promoters

Promoter & promoter group

76.15%5 named
HolderStakeSharesValue (₹ Cr)
40.35%4,55,70,360₹3.85k Cr
21.16%2,39,03,550₹2.02k Cr
5.72%64,60,747₹545.5 Cr
4.47%50,53,140₹426.7 Cr
4.45%50,25,000₹424.3 Cr

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

8.86%4 named
HolderStakeSharesValue (₹ Cr)
2.95%33,37,482₹281.8 Cr
2.57%29,02,744₹245.1 Cr
2.14%24,16,427₹204.0 Cr
1.20%13,60,000₹114.8 Cr

DII (other)

Insurance, banks, AIF, other domestic institutions

10.18%No names

No named holders ≥1% in this bucket.

Mutual Funds

Domestic mutual funds & UTI

5.47%1 named
HolderStakeSharesValue (₹ Cr)
1.85%20,85,880₹176.1 Cr

Retail & others

Holders below 1% disclosure threshold and public non-institutions

6.39%

SEBI requires naming only shareholders with ≥1% stake. The remaining 6.39% includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

Super Investors

Curated tracked investor profiles

1.33%1 named
HolderStakeSharesValue (₹ Cr)
1.33%15,00,117₹126.7 Cr

FII / FPI

Foreign portfolio investors

1.81%No names

No named holders ≥1% in this bucket.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.